Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a patient with severe atopic dermatitis experienced significant improvement with dupilumab after other treatments, including immunosuppressive agents, failed to control the disease.

This review discusses the role of PPAR-γ in the pathogenesis of primary cicatricial alopecia, including its involvement in lichen planopilaris and treatment trials using PPAR-agonists, and reports no new clinical results.

The study reported that vismodegib showed significant effectiveness in treating basal cell carcinoma, particularly in patients with Gorlin-Goltz syndrome or locally advanced BCC, but also highlighted substantial side effects, requiring careful management to prevent treatment resistance and maintain remission.

This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.

In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

This review reports that topical tacrolimus appears to be a safe and effective short-term treatment for inflammatory skin disorders, though further study is needed to assess long-term safety and efficacy.

This study found that in patients with alopecia areata and atopic dermatitis, 61.5% showed improvement with dupilumab treatment, but 38.5% experienced worsened or new-onset alopecia areata, with higher baseline IgE levels linked to better responses.

This study explored the creation of 3D-printed baricitinib pills using polylactic acid and found that the doughnut-shaped tablets increased surface area and drug release, with 59% released from the higher concentration pill over 24 hours.

This editorial reviews how photobiomodulation therapy might effectively treat both hyperpigmentation and depigmentation skin disorders, but reports no new clinical results.

In this research, RNA expression analysis of scalp biopsies from lichen planopilaris patients revealed changes in specific genes after treatments with hydroxychloroquine, narrow band UVB, or low level laser light therapy, suggesting potential biomarkers and implicating M2 macrophages in the disease's immunopathogenesis.

This study found that medroxyprogesterone injections led to partial or complete hair regrowth in some Pomeranian dogs with alopecia X, though their IGF-1 levels remained unchanged.

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

Both amodimethicone and dimethicone copolyol amine are effective hair conditioners.

In this study, the researchers used a human hair follicle model to demonstrate that T cell stimulation can induce an alopecia areata–like phenotype, with cell proliferation and immune privilege collapse; however, the DHODH inhibitor farudodstat partially mitigated these effects by reducing T cell proliferation.

This study found that the dissolution profiles of different finasteride polymorphs may affect the quality of finasteride capsules, highlighting the need for polymorphic quality control.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

This review synthesizes cases of biopsy-confirmed alopecia areata occurring in patients using IL-17 or IL-23 inhibitors, suggesting the need for increased awareness and further investigation into this rare adverse event.

In a murine model of alopecia areata, this study observed that the IL-2 fusion protein HCW9302 helped prevent disease development by expanding regulatory T cells and reducing disease-causing effector T cell infiltrates, suggesting potential for using IL-2 fusion proteins in alopecia areata treatment.

This case report describes a patient who developed severe alopecia and a rash after increasing captopril dosage, which resolved upon discontinuing the medication.

This study found that the CTLA-4 gene polymorphism (rs733618) has no association with polycystic ovarian syndrome in the studied population.

This review discusses the preclinical and clinical data on teriflunomide for multiple sclerosis, highlighting its selective action on immune cells without causing clinical immune suppression, and provides no new clinical results.

A woman's hair grew back after she stopped taking the Parkinson's disease medication pramipexole.

This review examines various immunomodulatory therapies for cutaneous lymphoma and notes that they are most effective in the disease's early stages.

This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.

The study found that both mometasone and calcipotriol ointments effectively reduced alopecia severity in localized alopecia areata, with calcipotriol having fewer side effects, while tacrolimus showed no significant effect.

This study found that the carbohydrate-based excipient β-cyclodextrin forms a stable inclusion complex with the active ingredient of Minoxicapil®, potentially enhancing its formulation for hair-loss treatment, and in vitro assays suggest improved proliferation of DPC cells, supporting its use in topical treatments.

This document provides a legal disclaimer and offers no research findings.

This study reports that combining baricitinib with low-dose cyclosporine and steroids resulted in effective and safe treatment for a case of alopecia totalis, maintaining hair regrowth without adverse effects.

Dupilumab can help regrow hair in alopecia areata but stopping it may cause hair loss again.